Abstract 18 F-fluorodeoxyglucose (FDG) PET/CT is a pivotal imaging modality for cancer
imaging, assisting diagnosis, staging of patients with newly diagnosed malignancy …

Introduction The present web-based national survey aims to assess the clinician's
perspective toward (1) the indications to perform positron emission tomography/computed …

Objective: To determine the prevalence and clinical features of pathologically proven
incidental cancer (IC) detected by whole-body fluorine-18 fludeoxyglucose (18F-FDG) …

Purpose The sensitivity of [18F] fluorodeoxyglucose positron emission tomography-
computed tomography (18F-FDG PET/CT) for detecting hepatocellular carcinoma (HCC) has …

18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography
(PET/CT) examinations are executed for several oncological applications [1]. In most cases …

Aims To prospectively evaluate the use of 18 F-fluorodeoxyglucose positron emission
tomography/computed tomography (18 F-FDG-PET/CT) in the definition of the treatment …

Because only pathologic examination can confirm the presence or absence of malignant
disease in cancer patients, a certain rate of misinterpretation in any kind of imaging study is …

Objective It is unclear whether the receptor status of breast malignancy or the proportion of
receptors expression is useful in the interpretation of 18F-FDG PET/CT. This study's purpose …

Purpose To investigate how frequently and when referring physicians follow the
recommendation in an 18 F-fluoro-2-deoxy-D-glucose PET/CT (FDG-PET/CT) report and to …

Aim: To elucidate techniques most commonly used for interpreting oncologic PET/CT
studies. This survey forms a basis to work on standardization of reporting and highlight the …